论文部分内容阅读
原发性肝癌恶性程度高,发展迅速,发病隐慝.在无普查条件下的切除率仍徘徊在20%左右.对于不能手术切除的肝癌病例的治疗仍是今后肝癌治疗中的重点课题.对于抗肿瘤药物,到目前为止仍缺乏一种对肿瘤有特异性的抗癌药物,因此只有通过载体将抗癌药物选择性地导向靶组织(肿瘤组织).现今研究多集中在与抗肿瘤相关的单克隆抗体(McAb)方面,但仍处于实验阶段.而化疗性栓塞治疗目前已成为治疗转移性肝癌的主要手段.1 化疗栓塞性微球肝动脉末梢栓塞的解剖学基础原发性肝癌95%～100%由动脉供血,而正常肝组织则由动脉、门静脉双重供血,为肝癌的断血治疗提供了解剖学基础.阻断肝动脉血流后;肿瘤90%～95%发生坏死而肝组织仅轻度受损.
Primary liver cancer has a high degree of malignancy, rapid development, and concealment of the disease. The resection rate is still around 20% in the absence of census. The treatment of unresectable liver cancer cases is still a key topic in the treatment of liver cancer in the future. Anti-tumor drugs have so far lacked an anticancer drug that is specific for tumors. Therefore, only anticancer drugs are selectively targeted to target tissues (tumor tissues) through carriers. Today’s studies are mostly focused on anti-tumor-related drugs. Monoclonal antibody (McAb), but still in the experimental stage. Chemotherapy embolization therapy has become the main means of treatment of metastatic liver cancer.1 Anatomical basis of hepatic arterial peripheral embolism for chemoembolization microspheres Primary liver cancer 95% ~100% of blood supply is from arteries, while normal liver tissue is supplied by arteries and portal veins, which provides anatomical basis for treatment of liver cancer. After blocking hepatic artery blood flow, 90%-95% of tumors have necrosis and liver tissue. Only mildly damaged.